The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and pioglitazone processes for the preparation thereof and their use to treat certain diseases.

The invention is directed to an extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch.

A method for preventing stroke in a patient suffering from atrial fibrillation wherein the patient has no risk factors for major bleeding events the method comprising administering to the patient a dosage of >150 mg b.i.d. to 300 mg b.i.d. of dabigatran etexilate optionally in the form of a pharmaceutically acceptable salt thereof.

The invention is directed to an extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix the matrix comprising at least two water swelling polymers wherein one of said polymers is pregelatinized starch and wherein another one of said polymers is an anionic polymer.

This invention relates to bicyclic ring system substituted sulfonamide functionalized phenols of general formula 1 their use as inhibitors of CXCR2 activity pharmaceutical compositions containing the same and methods of using the same as agents for treatment and/or prevention of respiratory or gastrointestinal complaints or diseases inflammatory diseases of the joints skin or eyes diseases of the peripheral or central nervous system or cancers as well as pharmaceutical compositions which contain...

The instant invention relates to the use of tiotropium salts for the manufacture of a medicament for the treatment of patients suffering from severe persistent asthma.

The invention relates to a bilayer pharmaceutical tablet comprising a first layer containing 3 to 50 wt. % of telmisartan dispersed in a dissolving tablet matrix and a second layer containing a diuretic in a disintegrating tablet matrix as well as a processes for producing same.

The invention relates to new solid pharmaceutical compositions comprising the angiotensin II receptor antagonist telmisartan a basic agent a surfactant or emulsifier and a water-soluble diluent e.g. in form of granules or in form of a powder as well as solid oral formulations ready for use/ingestion e.g. capsule and tablet formulations made from said pharmaceutical compositions and methods for producing said compositions and formulations making use of a fluid-bed granulation process or of a spra...

The invention is directed to an extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch.